| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| ln Vitro |
Methylnitrosoguanidine (MNNG, 0-1100 nM; 24 h) exerts toxic and mutagenic effects on three human diploid lymphoblastoid cell lines, MIT-2, WI-L2, and GM 130 [1].
|
|---|---|
| ln Vivo |
Methylnitrosoguanidine (MNNG; 200 mg/kg; po) enhances the number of rises in Wistar albinos [2].
|
| Animal Protocol |
Animal/Disease Models: Male Wistar albino rat [2]
Doses: 200 mg/kg Route of Administration: po (po (oral gavage)) at 0 Day 14 Experimental Results: The incidence of gastric cancer in Wistar albino rats was 100%. |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Following oral administration of 14C-labeled N-methyl-N'-nitro-N-nitrosoguanidine, most of the radioactive material is excreted in the urine within 24 hours, with less than 3% excreted in the feces. Between 24 and 48 hours later, less than 3% of the radioactive material remains in the body as acid-insoluble substances. Metabolism/Metabolites Following oral administration of MNNG, approximately 90% of MNNG is excreted in the urine within the first 9 hours, primarily as N-methyl-N'-nitroguanidine. Evidence suggests that the denitrosation of MNNG is mediated by enzymes in the stomach, liver, and kidneys. |
| References |
|
| Additional Infomation |
According to an independent committee of scientific and health experts, N-methyl-N'-nitro-N-nitrosoguanidine is potentially carcinogenic. N-methyl-N'-nitro-N-nitrosoguanidine is a yellow powder with a melting point of 244°F (113°C), decomposing above 212°F (100°C). It is a suspected carcinogen and has extremely strong mutagenic properties. Avoid skin contact and inhalation of its vapors. It is usually stored in sealed polyethylene bottles in metal containers, frozen (below 32°F/0°C). Long-term storage may cause decomposition and generate sufficient pressure for an explosion within a sealed container. Keep away from heat, sparks, and open flames. N-methyl-N'-nitro-N-nitrosoguanidine is an N-nitroguanidine compound with a nitroso and methyl substituent at the N' position. It is an alkylating agent. It is functionally related to nitroguanidine. A nitrosoguanidine derivative with strong mutagenic and carcinogenic properties.
Mechanism of Action In vitro and in vivo, MNNG induces nucleic acid methylation, primarily producing 7-methylguanine, with minor amounts of 3-methyladenine, 1-methyladenine, 3-methylcytosine, and (6)o-methylguanine. …MNNG can modify proteins by transferring its nitroguanidine residues, for example, converting lysine to nitroarginine. Modified cytochrome C no longer acts as an electron acceptor. After MNNG treatment, histones in ascites tumor cells contain nitroarginine. |
| Molecular Formula |
C2H5N5O3
|
|---|---|
| Molecular Weight |
147.0928
|
| Exact Mass |
147.039
|
| CAS # |
70-25-7
|
| PubChem CID |
135436526
|
| Appearance |
Light yellow to yellow solid-liquid Mixture
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
207.8±23.0 °C at 760 mmHg
|
| Melting Point |
118°C (dec.)
|
| Flash Point |
79.5±22.6 °C
|
| Vapour Pressure |
0.2±0.4 mmHg at 25°C
|
| Index of Refraction |
1.641
|
| LogP |
-0.79
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
10
|
| Complexity |
161
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[O-][N+](N([H])/C(=N/[H])/N(C([H])([H])[H])N=O)=O
|
| InChi Key |
VZUNGTLZRAYYDE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C2H5N5O3/c1-6(5-8)2(3)4-7(9)10/h1H3,(H2,3,4)
|
| Chemical Name |
1-methyl-3-nitro-1-nitrosoguanidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~849.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (14.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (14.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (14.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7986 mL | 33.9928 mL | 67.9856 mL | |
| 5 mM | 1.3597 mL | 6.7986 mL | 13.5971 mL | |
| 10 mM | 0.6799 mL | 3.3993 mL | 6.7986 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
